SCHEMBL2178008

SCHEMBL2178008

CC(C)C(C(=O)O)N1Cc2cc(-c3ccc(NC(=S)Nc4cccc(C(F)(F)F)c4)cc3)ccc2C1=O

nearest known ligand 0.49

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
DGAT1 O75907 5/20 0.49
THRB P10828 1/20 0.46
ALDH1A1 P00352 4/20 0.44
HTT P42858 1/20 0.44
GAA P10253 3/20 0.43
MAPT P10636 3/20 0.42
TDP1 Q9NUW8 2/20 0.42
KDM4E B2RXH2 1/20 0.42
SMN1; SMN2 Q16637 1/20 0.42
SDCBP O00560 2/20 0.41
SDC2 P34741 2/20 0.41
NPSR1 Q6W5P4 1/20 0.41
L3MBTL1 Q9Y468 1/20 0.41
TP53 P04637 2/20 0.41
LMNA P02545 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2181755 1.00 DGAT1 (0.49) DGAT1THRBALDH1A1HTTGAA
SCHEMBL2178767 0.93 THRB (0.46) DGAT1THRBALDH1A1HTTGAA
SCHEMBL2179086 0.93 THRB (0.46) DGAT1THRBALDH1A1HTTGAA
SCHEMBL2178541 0.93 DGAT1 (0.54) DGAT1THRBHTTMAPTKDM4E
SCHEMBL2182706 0.93 DGAT1 (0.54) DGAT1THRBHTTMAPTKDM4E
SCHEMBL2178546 0.93 DGAT1 (0.54) DGAT1THRBHTTMAPTKDM4E
SCHEMBL2180663 0.89 DGAT1 (0.47) DGAT1THRBHTTGAAMAPT
SCHEMBL2179511 0.89 DGAT1 (0.47) DGAT1THRBHTTGAAMAPT
SCHEMBL2177059 0.87 SDCBP (0.52) DGAT1ALDH1A1SDCBPSDC2TP53
SCHEMBL2177051 0.87 SDCBP (0.52) DGAT1ALDH1A1SDCBPSDC2TP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8748426-B2 Inhibitors of diacylglycerol acyl transferase Piramal Enterprises Limited (IN) 2014-06-10 US claimed
US-20120289505-A1 INHIBITORS OF DIACYLGLYCEROL ACYL TRANSFERASE Piramal Enterprises Limited (IN) 2012-11-15 US claimed
EP-2519500-A1 INHIBITORS OF DIACYLGLYCEROL ACYL TRANSFERASE Piramal Healthcare Ltd. (IN) 2012-11-07 EP claimed
WO-2011080718-A1 INHIBITORS OF DIACYLGLYCEROL ACYL TRANSFERASE PIRAMAL LIFE SCIENCES LIMITED (IN) 2011-07-07 WO claimed
US-8748426-B2 Inhibitors of diacylglycerol acyl transferase Piramal Enterprises Limited (IN) 2014-06-10 US disclosed
US-20120289505-A1 INHIBITORS OF DIACYLGLYCEROL ACYL TRANSFERASE Piramal Enterprises Limited (IN) 2012-11-15 US disclosed
EP-2519500-A1 INHIBITORS OF DIACYLGLYCEROL ACYL TRANSFERASE Piramal Healthcare Ltd. (IN) 2012-11-07 EP disclosed
WO-2011080718-A1 INHIBITORS OF DIACYLGLYCEROL ACYL TRANSFERASE PIRAMAL LIFE SCIENCES LIMITED (IN) 2011-07-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120289505-A1 INHIBITORS OF DIACYLGLYCEROL ACYL TRANSFERASE DGAT1, DGAT2, LCAT DGAT1 1/4885THRB 2612/4885ALDH1A1 715/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.